Genetic diagnosis of familial breast cancer using clonal sequencing

Using conventional Sanger sequencing as a reference standard, we compared the sensitivity, specificity, and capacity of the Illumina GA II platform for the detection of TP53, BRCA1, and BRCA2 mutations in established tumor cell lines and DNA from patients with germline mutations. A total of 656 coding variants were identified in four cell lines and 65 patient DNAs. All of the known pathogenic mutations (including point mutations and insertions/deletions of up to 16 nucleotides) were identified, using a combination of the Illumina data analysis pipeline with custom and commercial sequence alignment software. In our configuration, clonal sequencing outperforms current diagnostic methods, providing a reduction in analysis times and in reagent costs compared with conventional sequencing. These improvements open the possibility of BRCA1/2 testing for a wider spectrum of at‐risk women, and will allow the genetic classification of tumors prior to the use of novel PARP inhibitors to treat BRCA‐deficient breast cancers. Hum Mutat 31:1–8, 2010. © 2010 Wiley‐Liss, Inc.

[1]  James R. Knight,et al.  Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.

[2]  Matthew J. Huentelman,et al.  IDENTIFICATION OF GENETIC VARIANTS USING BARCODED MULTIPLEXED SEQUENCING , 2008, Nature Methods.

[3]  G. Weinstock,et al.  Direct selection of human genomic loci by microarray hybridization , 2007, Nature Methods.

[4]  R. Altman,et al.  Direct‐to‐Consumer Genetic Testing: Failure Is Not an Option , 2009, Clinical pharmacology and therapeutics.

[5]  I. Tikhonova,et al.  Genetic diagnosis by whole exome capture and massively parallel DNA sequencing , 2009, Proceedings of the National Academy of Sciences.

[6]  R. Green,et al.  Direct to consumer genetic testing: Avoiding a culture war , 2009, Genetics in Medicine.

[7]  P Green,et al.  Base-calling of automated sequencer traces using phred. II. Error probabilities. , 1998, Genome research.

[8]  N. Curtin,et al.  PARP inhibitors for cancer therapy , 2005, Expert Reviews in Molecular Medicine.

[9]  Emily H Turner,et al.  Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes , 2009, Nature.

[10]  Francisco M. De La Vega,et al.  Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. , 2009, Genome research.

[11]  R. Hornik,et al.  Risk Information Exposure and Direct-to-Consumer Genetic Testing for BRCA Mutations among Women with a Personal or Family History of Breast or Ovarian Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[12]  P. Shannon,et al.  Exome sequencing identifies the cause of a Mendelian disorder , 2009, Nature Genetics.

[13]  L. Sequist,et al.  EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. , 2008, Annual review of medicine.

[14]  F. Stewart,et al.  How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network , 2007, European Journal of Human Genetics.

[15]  J. Maguire,et al.  Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.

[16]  Nancy F. Hansen,et al.  Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry , 2008, Nature.

[17]  J. Seidman,et al.  Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection , 2009, Nature Methods.

[18]  B. Shields,et al.  Semi-automated unidirectional sequence analysis for mutation detection in a clinical diagnostic setting. , 2009, Genetic testing and molecular biomarkers.

[19]  S. Weissman,et al.  A polymerase chain reaction approach for constructing jumping and linking libraries. , 1990, Nucleic acids research.

[20]  P. Green,et al.  Base-calling of automated sequencer traces using phred. I. Accuracy assessment. , 1998, Genome research.